{
    "id": "0752",
    "question": "A 47-year-old woman with metastatic breast cancer who is undergoing chemotherapy comes to the physician for a follow-up exam. She reports extreme fatigue since beginning her chemotherapy regimen. Her pulse is 98/min, respirations are 16/min, and blood pressure is 132/84 mm Hg. Her hemoglobin is 10.4 g/dL, leukocyte count is 800/mm3 with 5% monocytes, and platelet count is 50,000/mm3. The patient is started on a new medication. One week later, serum studies show a hemoglobin of 10.6 g/dL, a leukocyte count of 2,000/mm3 with 2% monocytes, and a platelet count of 56,000/mm3. Which of the following drugs is the most likely cause of these findings?",
    "options": {
        "A": "Aldesleukin",
        "B": "Interferon beta",
        "C": "Filgrastim",
        "D": "Romiplostim"
    },
    "answer": "C",
    "predict": "To determine the most likely cause of the patient's lab results, let's analyze the information step by step: 1. **Initial lab results**: The patient has anemia (Hemoglobin: 10.4 g/dL), leukopenia (Leukocyte count: 800/mm3 with 5% monocytes), and thrombocytopenia (Platelet count: 50,000/mm3). These findings are consistent with chemotherapy-induced side effects. 2. **New medication**: The patient is started on a new medication, and one week later, there's an improvement in anemia (Hemoglobin: 10.6 g/dL), but worsening of leukopenia (Leukocyte count: 2,000/mm3 with 2% monocytes) and thrombocytopenia (Platelet count: 56,000/mm3). 3. **Analysis of options**: - **Aldesleukin (Prokaryon)**: This is an interleukin-2 (IL-2) analog used primarily in the treatment of metastatic melanoma. IL-2 can cause lymphocytosis (increased leukocyte count) as a side effect, which is opposite of the patient's worsening leukopenia. So, this is unlikely. - **Interferon beta**: Interferon beta is used in the treatment of multiple sclerosis and some cancers. It can cause leukopenia and thrombocytopenia as side effects, but it's not typically associated with anemia improvement. So, this is also unlikely. - **Filgrastim**: Filgrastim is a granulocyte-colony stimulating factor (G-CSF) used to stimulate the production of white blood cells, particularly neutrophils. It's commonly used to prevent neutropenia caused by chemotherapy. This could explain the improvement in anemia and worsening of leukopenia, but it doesn't fully account for the thrombocytopenia. - **Romiplostim**: Romiplostim is a thrombopoietin receptor agonist used to stimulate platelet production in patients with thrombocytopenia. It can cause thrombocytosis (increased platelet count) as a side effect, which aligns with the patient's worsening thrombocytopenia. Given the improvement in anemia and worsening of leukopenia and thrombocytopenia, the most likely cause of these findings is a medication that stimulates platelet production. **Romiplostim** is the most likely cause, as it is a thrombopoietin receptor agonist that can cause thrombocytosis. **Output:** ```json { \"step_by_step_thinking\": \"The patient's improvement in anemia and worsening of leukopenia and thrombocytopenia suggest a medication that stimulates platelet production. Romiplostim is a thrombopoietin receptor agonist used to stimulate platelet production, making it the most likely cause of these findings.\", \"answer_choice\": \"D\" } ```",
    "snippets": [],
    "scores": [],
    "execution_time": 45.0488224029541
}